Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thrombophob Ointment
- Development stage
- Unknown
- Lead developer
- PT Tunggal Idaman Abadi
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Thrombophob Ointment is a topical combination therapy containing heparin sodium (an anticoagulant) and benzyl nicotinate (a vasodilator). It is primarily indicated for the treatment of superficial thrombophlebitis, superficial thrombosis, hematomas, bruises, contusions, sprains, tendovaginitis, frostbite, and varicose vein-related discomfort. Heparin sodium acts by binding to antithrombin III, which accelerates the inactivation of clotting factors such as thrombin and factor Xa, thereby preventing clot formation and promoting the resolution of existing superficial micro-clots. Benzyl nicotinate acts as a vasodilator by activating hydroxycarboxylic acid receptors (HCAR2 and HCAR3), which increases local blood flow and cutaneous absorption of heparin, enhancing its therapeutic efficacy and relieving localized pain and swelling. Originally developed by Nordmark, Thrombophob Ointment is marketed and manufactured by various regional partners, including Tunggal Idaman Abdi in Indonesia and Zydus Healthcare in India.
- Brand names
- ThrombophobThrombophob Ointment
- Other names
- benzyl nicotinate + heparinbenzyl nicotinate + heparin sodiumheparin + benzyl nicotinateheparin sodium + benzyl nicotinate
02
Targets
ATIII (Antithrombin III)HCAR2 (Hydroxycarboxylic acid receptor 2)HCAR3 (Hydroxycarboxylic acid receptor 3)
Beyond the preview
Go deeper on Thrombophob Ointment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thrombophob Ointment.